Issue: May 2017
April 03, 2017
2 min read
Save

Tofacitinib Combination Therapy led to Improvements in Patient-reported Outcomes

Issue: May 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Tofacitinib combined with conventional disease-modifying antirheumatic drug therapy led to improvements in patient-reported outcomes, according to a recently published phase 3 trial.

Perspective from Joseph Flood, MD

Vibeke Strand, MD, at the Stanford University School of Medicine, and colleagues performed a 12-month phase 3 trial — called ORAL SYNC — of 795 patients with active rheumatoid arthritis who had a previous inadequate response to therapy with at least one disease-modifying antirheumatic drug (DMARD). Patients were randomized 4:4:1:1 to receive — for two times per day — either 5 mg of tofacitinib, 10 mg tofacitinib, placebo advanced to 5 mg tofacitinib or placebo advanced to 10 mg tofacitinib all in combination with background DMARD therapy. Patient-reported outcomes included patient global assessment of arthritis (PtGA), patient assessment of arthritis pain, Health assessment questionnaire disability index (HAQ-DI), SF-36, functional assessment of chronic illness therapy-fatigue (FACIT-F) and medical outcomes study sleep (MOS Sleep).

Vibeke Strand, MD
Vibeke Strand

At 3 months, there were significant improvements vs. placebo in PtGA, pain, HAQ-DI, eight SF-36 domains, FACIT-F and MOS Sleep in the 10-mg group and improvements in PtGA, pain, HAQ-DI, seven SF-36 domains, FACIT-F and MOS Sleep in the 5-mg group, which were sustained through 12 months. At 3 months, significantly more patients treated with tofacitinib reported improvements of greater than or equal to the minimum clinically important differences vs. placebo for all patient-reported outcomes, except for the SF-36 emotional domain, which remained significant for the 10-mg group only. – by Will Offit

Disclosure: Strand reports she received consulting fees and is an advisory board member for AbbVie, Amgen, Biogen Idec, BMS, Crescendo, Genentech/Roche, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer Inc., Regeneron, Sanofi, Takeda, UCB and Vertex; received consulting fees from Alder, AstraZeneca, Biotest, Celgene, Celltrion, Corrona LLC, Horizon, Hospira, Incyte, Merck, Serono and Protalex.